CONFERENCE HIGHLIGHTS |
|
Express Scripts’ Aimee Tharaldson, PharmD, discussed key market trends for the specialty drug pipeline in Session 102. While the specialty drug pipeline is robust, there are also 39 brand drugs losing patents through 2018, presenting a $13 billion generic opportunity. Read more |
|
Four years have passed since the U.S. biosimilar pathway opened up as part of the ACA and two years since FDA issued its draft guidance reports on developing biosimilar products. But so far, no manufacturer has pushed a product through. A panel of experts will speculate on the future of biosimilars in the U.S. marketplace at Session 202 at AMCP today. Read more |
|
When payers and pharmacy benefits managers collaborate on medication therapy management (MTM), they can drive positive impact on readmission rates. A Catamaran-Health New England partnership achieved a 30% reduction in 30-day readmissions, according to panelist David Calabrese, vice president and chief pharmacy officer for Catamaran, presenting at Session 216 today. Read more |
|
As evidence and clinical guidelines for the treatment of multiple myeloma bump up against the introduction of promising new agents, payers face the challenge of providing sufficient coverage that meets the needs of a patient population while maintaining the ability to pay for it. Symposium (SS1), “Control Versus Care,” highlighted payer and provider perspectives on treatment and a desire by both for collaboration. Read more |
|
Telephonic intervention for members with high controlled-substance utilization appears to result in substantial decreases in utilization and cost, according Prime Therapeutics. The PBM presented its study results at AMCP, revealing that savings totaled $220 per member over a three-month period with health plan-directed, pharmacist-prescriber interventions. Read more |
|
|
